Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TFX06 in ER+/HER2- Advanced Breast Cancer
NCT05927779Phase 2Unknown
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TFX06 in breast cancer, sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Status: unknown.
02
Drugs
TFX06
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05927779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927779.